Rice Hall James & Associates LLC Lowers Holdings in Reata Pharmaceuticals Inc (NASDAQ:RETA)

Rice Hall James & Associates LLC decreased its position in Reata Pharmaceuticals Inc (NASDAQ:RETA) by 5.9% in the second quarter, Holdings Channel reports. The firm owned 109,131 shares of the company’s stock after selling 6,787 shares during the period. Rice Hall James & Associates LLC’s holdings in Reata Pharmaceuticals were worth $10,297,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Optimum Investment Advisors purchased a new stake in shares of Reata Pharmaceuticals in the second quarter valued at approximately $76,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Reata Pharmaceuticals by 100.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 991 shares of the company’s stock valued at $85,000 after purchasing an additional 496 shares during the period. SG3 Management LLC purchased a new stake in shares of Reata Pharmaceuticals in the first quarter valued at approximately $128,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Reata Pharmaceuticals in the first quarter valued at approximately $186,000. Finally, Legal & General Group Plc boosted its holdings in shares of Reata Pharmaceuticals by 11.5% in the fourth quarter. Legal & General Group Plc now owns 3,414 shares of the company’s stock valued at $192,000 after purchasing an additional 352 shares during the period. Hedge funds and other institutional investors own 54.71% of the company’s stock.

A number of brokerages recently issued reports on RETA. Zacks Investment Research lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 11th. Citigroup boosted their price target on Reata Pharmaceuticals from $190.00 to $194.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, BidaskClub lowered Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Reata Pharmaceuticals has an average rating of “Buy” and a consensus price target of $141.50.



In related news, CFO Jason Douglas Wilson sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $83.54, for a total value of $334,160.00. Following the completion of the transaction, the chief financial officer now owns 4,000 shares of the company’s stock, valued at $334,160. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Elaine Castellanos sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $85.20, for a total transaction of $170,400.00. Following the completion of the transaction, the insider now directly owns 4,138 shares of the company’s stock, valued at approximately $352,557.60. The disclosure for this sale can be found here. Insiders sold 10,000 shares of company stock valued at $843,120 in the last three months. 34.40% of the stock is currently owned by insiders.

NASDAQ:RETA traded up $0.89 during trading hours on Thursday, reaching $73.76. The company’s stock had a trading volume of 4,926 shares, compared to its average volume of 189,539. The stock has a market cap of $2.36 billion, a P/E ratio of -25.88 and a beta of 2.31. Reata Pharmaceuticals Inc has a 12 month low of $47.50 and a 12 month high of $104.53. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 5.23. The firm has a 50 day simple moving average of $87.72.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.02). The business had revenue of $7.83 million during the quarter, compared to the consensus estimate of $7.76 million. Reata Pharmaceuticals had a negative return on equity of 748.31% and a negative net margin of 410.38%. On average, analysts expect that Reata Pharmaceuticals Inc will post -4.58 EPS for the current fiscal year.

Reata Pharmaceuticals Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

See Also: What is insider trading?

Want to see what other hedge funds are holding RETA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reata Pharmaceuticals Inc (NASDAQ:RETA).

Institutional Ownership by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.